Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen
1616493-44-7Nc1cc(F)ccc1NC(=O)c1ccc(CNC(=O)/C=C/c2cccnc2)cc1SZMJVTADHFNAIS-BJMVGYQFSA-NChidamide is a member of benzamides.
Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
L - Antineoplastic and immunomodulating agents
QL - Antineoplastic and immunomodulating agents
Chidamide is an orally bioavailable histone deacetylase (HDAC) inhibitor derived from the benzamide class. Histone deacetylase inhibitors are a class of cancer drugs that induce selective regulation of gene expression in cancer cells. [HUYA Biosciences Press Release]
BeschreibungChidamide is an inhibitor of histone deacetylases (HDACs; IC50s = 0.095, 0.160, 0.067, 0.733, 0.078, and 0.432 μM for HDAC1-3, 8, 10, and 11, respectively). It is selective for these HDACs over HDAC4-7 and 9 (IC50s = >30 μM for all). Chidamide also inhibits nicotinamide phosphoribosyltransferase (Nampt; IC50 = 2.1 μM). It inhibits cell growth in a panel of 18 cancer cell lines (GI50s = 0.4-40 μM) but has no effect on the growth of non-cancerous CCC-HEK human fetal kidney or CCC-HEL human liver cells (GI50s = >100 μM). In vivo, tucidinostat (12.5, 25, and 50 mg/kg) reduces tumor growth in HCT-8, A549, BEL-7402, and MCF-7 mouse xenograft models.
VerwendenChidamide is a newly designed histone deacetylase inhibitor that induces an antitumor effect in various cancer by increasing the acetylation levels of histone H3 and decrease histone deacetylase (HDAC) activity, induces apoptosis. Also, it is a potential utility of Chidamide for the treatment of Myelodysplastic syndromes.
Keine Reaktionsaufzeichnungen unter den aktuellen Filterkriterien.
Wird geladen…
1616493-44-7DTXSID701032295CHEMBL3621988CHEBI:135918